Risk Factors for Cervical Precancer and Cancer in HIV-Infected, HPV-Positive Rwandan Women by Anastos, Kathryn et al.
Risk Factors for Cervical Precancer and Cancer in HIV-
Infected, HPV-Positive Rwandan Women
Kathryn Anastos
1*, Donald R. Hoover
2, Robert D. Burk
3, Antonio Cajigas
4, Qiuhu Shi
5, Diljeet K. Singh
6,
Mardge H. Cohen
7, Eugene Mutimura
8, Charles Sturgis
9, William C. Banzhaf
10, Philip E. Castle
11
1Departments of Medicine and Epidemiology and Population Health, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, United States of
America, 2Department of Statistics and Institute for Health, Health Care Policy and Aging Research, Rutgers University, Piscataway, New Jersey, United States of America,
3Division of Genetics, Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, United States of America, 4Department of Pathology, Montefiore
Medical Center andAlbertEinsteinCollegeofMedicine,Bronx, NewYork, United Statesof America, 5DepartmentofEpidemiologyandCommunity Health,New York Medical
College, Valhalla, New York, United States of America, 6Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, 7John Stroger
(formerly Cook County) Hospital and Rush University, Chicago, Illinois, United States of America, 8Women’s Equity in Access to Care and Treatment, Kigali, Rwanda,
9Providence Regional Medical Center, Everette, Washington, United States of America, 10University of Chicago Pritzker School of Medicine, Evanston, Illinois, United States
of America, 11National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America
Abstract
Background: Although cervical cancer is an AIDS-defining condition, infection with human immunodeficiency virus (HIV)
may only modestly increase the risk of cervical cancer. There is a paucity of information regarding factors that influence the
natural history of human papillomavirus (HPV) in HIV-infected women. We examined factors associated with cervical
intraepithelial neoplasia grade 3 or cancer (CIN3+) in Rwandan women infected with both HIV and HPV (HIV+/HPV+).
Methods: In 2005, 710 HIV+ Rwandan women $25 years enrolled in an observational cohort study; 476 (67%) tested HPV+.
Each woman provided sociodemographic data, CD4 count, a cervical cytology specimen and cervicovaginal lavage (CVL),
which was tested for .40 HPV genotypes by MY09/MY11 PCR assay. Logistic regression models calculated odds ratios (OR)
and 95% confidence intervals (CI) of associations of potential risk factors for CIN3+ among HIV+/HPV+ women.
Results: Of the 476 HIV+/HPV+ women 42 (8.8%) were diagnosed with CIN3+. Factors associated with CIN3+ included $7
(vs. 0-2) pregnancies, malarial infection in the previous six months (vs. never), and $7 (vs. 0-2) lifetime sexual partners.
Compared to women infected by non-HPV16 carcinogenic HPV genotypes, HPV16 infection was positively associated and
non-carcinogenic HPV infection was inversely associated with CIN3+. CD4 count was significantly associated with CIN3+
only in analyses of women with non-HPV16 carcinogenic HPV (OR=0.62 per 100 cells/mm
3, CI=0.40-0.97).
Conclusions: In this HIV+/HPV+ population, lower CD4 was significantly associated with CIN3+ only in women infected with
carcinogenic non-HPV16. We found a trend for higher risk of CIN3+ in HIV+ women reporting recent malarial infection; this
association should be investigated in a larger group of HIV+/HPV+ women.
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Introduction
Cervical infections by carcinogenic human papillomavirus
(HPV) genotypes cause virtually all cervical cancer and its
immediate precursor lesion, cervical intraepithelial neoplasia
grade 3 (CIN3) [1–3]. Exposure to genital HPV is nearly universal
in sexually active people but the majority of infections clear within
1–2 years [4–6]. Persistence in women of a carcinogenic HPV type
(HR-HPV) increases the risk of cervical intraepithelial neoplasia
grade 3 (CIN3) and cancer [7]. A significant proportion of CIN3
will invade if not detected and treated [8].
Evidence suggests that secondary factors, or HPV cofactors,
influence the progression of HR-HPV infections to CIN3 and
cancer (CIN3+), including exogenous factors such as parity,
smoking tobacco and possibly oral contraceptive use [9]. Co-
infection by human immunodeficiency virus (HIV) may moder-
ately increase the risk of cervical cancer [10], as immunosuppres-
sion may compromise the ability of the host to clear the HPV
infection. The lack of a more profound impact of HIV on cervical
cancer rates may be explained by two findings: 1) the early natural
history of HPV16, the HPV genotype most often associated with
progression to carcinoma, appears to be minimally affected by the
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escape immune surveillance even in an immunocompetent host
[11–13]; and 2) increasing severity of immunosuppression only
modestly increases the likelihood of HPV persistence [12].
However, there is a paucity of information regarding factors that
influence the natural history of HPV in HIV-infected women.
We conducted a cross-sectional analysis of risk factors associated
with CIN3 and cancer in a population of HIV-infected Rwandan
women. We previously found in this population that HPV
prevalence and presence of cytologic abnormalities were inversely
associated with CD4 cell counts [13]. We limited the study
population to HIV-infected women with prevalent HPV, since
HR-HPV infection is required for the development of CIN3.
CIN3 was our primary endpoint because CIN3 is the best
surrogate for cancer risk and while CIN2 is the clinical threshold
for treatment, it is a poorly reproducible diagnosis of cervical
precancer [14–17].
Methods
Ethics Statement
Each participant provided written informed consent after
viewing a video demonstrating study procedures. The Rwanda
National Ethics Committee and the Institutional Review Board of
Montefiore Medical Center, Bronx, NY approved the study
protocol and the consent process.
Participants
The Rwanda Women’s Interassociation Study and Assessment
(RWISA) is an observational cohort study of 710 HIV-infected
and 226 HIV-uninfected Rwandan women enrolled May-
November, 2005. Methods have been previously described in
detail [13]. This analysis includes the 476 women co-infected with
HIV and HPV (HIV+/HPV+). At study entry, participants
provided historical information on sociodemographic characteris-
tics, physical examination was performed, and blood specimens
were taken for CD4 cell count, full blood count, and other
laboratory testing.
Participants underwent pelvic examinations. To minimize
contamination of gynecologic specimens by blood, exfoliated
cervical cells (used for HPV DNA testing) were obtained by
cervicovaginal lavage (CVL) prior to collection of a cervical
cytology specimen, as previously described [13]. Colposcopy was
provided to all women with any abnormal cytologic finding
including atypical cells of uncertain significance and cervical
biopsies were obtained for specific clinical indications: any visible
lesion, suspected malignancy, or cytologic interpretation of high-
grade squamous intraepithelial lesions (HSIL), atypical squamous
cells of uncertain significance with suspicion of HSIL, atypical
glandular cells, or cancer.
Clinical Laboratory Data
CD4 counts were measured at the National Reference
Laboratory of Rwanda by FACS Count (Becton Dickinson, San
Jose ´, CA).
HPV Testing
HPV testing was performed on CVL specimens taken at the
enrollment visit.
In brief, 100 ml of each CVL specimen was mixed (1:1) with a
26 solution of K buffer (containing Proteinase K at 400 g/mL,
2 mM EDTA, 2% Laureth-12, 100 mM Tris, pH 8.5) and
incubated at 55uC for 2 hours followed by a further incubation
at 95uC for 10 minutes. After the CVL specimens were digested
with Proteinase K, 10 mL of each cell digest was taken to detect
HPV DNA using the L1 MY09/MY11 modified PCR system with
AmpliTaq Gold polymerase as described elsewhere [18]. Ampli-
fication products were probed for the presence of any HPV DNA
by Southern blot with a radiolabeled generic probe mixture and
subsequently typed by dot blot hybridization for HPV 6, 11, 13,
16, 18, 26, 31–35, 39, 40, 42, 45, 51–59, 61, 62, 64, 66–74, 81–85,
89, and 97. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66
and 68 were considered the primary carcinogenic HPV genotypes.
Histopathology
Biopsies and excised tissue were read independently and blindly
by pathologists at Montefiore Medical Center in the Bronx, New
York or Evanston Hospital in Chicago Illinois, and were
categorized as Negative, CIN1, CIN2, CIN3, and cancer. We
used the most severe histopathologic diagnosis as the final
participant diagnosis. Among the 202 biopsies, 3 were diagnosed
as cancer, 39 CIN3, 21 CIN2, and 76 CIN1.
Statistical Analysis
Of the 710 HIV-infected women 476 (67.0%) tested positive for
any HPV DNA. Although non-carcinogenic HPV has not been
shown to be a cause of cervical cancer, we included those women
positive for non-carcinogenic HPV because some HPV genotypes
categorized as non-carcinogenic HPV may be borderline carci-
nogenic [19] and may cause CIN3 (with little chance of invasion)
particularly in HIV+ women [20]. We performed analyses on all
HPV+ women, women with carcinogenic HPV genotypes and
women with carcinogenic HPV genotypes other than HPV16.
Standard contingency table methods, with exact tests and when
appropriate Mantel extension trend tests assessed univariate
associations of categorical variables with CIN3 and cancer versus
,CIN3. Two-sided P values ,0.05 were considered statistically
significant. The associations of ordinally categorized continuous
variables with grade of neoplasia were assessed with logistic
regression and trend tests. Odds ratios (OR) and 95% confidence
intervals (CI) adjusted for variables identified in univariate analyses
were calculated using logistic regression. Multivariate logistic
regression models were fit using variables that had statistically
significant (P#0.05) unadjusted associations with CIN3+ and
women that had complete information on these variables: 454 of
476 (95.4%) women positive for any HPV; 303 of 316 (95.9%)
positive for carcinogenic HPV; and 241 of 251 (96.0%) women
with non-16 carcinogenic HPV. Because of the relationship of
CD4 counts with immunosuppression, all models included CD4
counts. We repeated these analyses with the outcome defined as
CIN2 or more severe (CIN2+) (n=63), including 21 women with
CIN2, an equivocal precancer diagnosis.
Results
Demographic and clinical characteristics of the included women
are shown in Table 1. Of the 476 HPV+ women, 223 had a
colposcopy and 202 had a cervical biopsy. Among women
diagnosed with CIN3+ (n=42; 39 CIN3, 3 cancer) the most
common HPV types detected were HVP16 (33%), HPV58 (26%),
HPV31 and 33 (21% each) and HPV 35 and 51 (19% each).
HPV52 was harbored by 4.8% and 64.3% were infected with
multiple HPV types, compared to 11.1% and 49.8% of women
with ,CIN3, respectively. Compared to women with a less severe
histologic diagnosis, women diagnosed with CIN3+ reported more
pregnancies (ptrend ,0.001) and lifetime sexual partners (ptrend =
0.03), shared their residence with more people (ptrend =0.01), had
a higher income (ptrend =0.02), were more likely to have had a
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infected women with and without cervical intraepithelial neoplasia grade 3 (CIN3) or cancer (CIN3+).
All (N=476) CIN3+ (n=42) ,CIN3 (n=434) CIN3+ vs. ,CIN3
N % n % n % p ptrend
Age Category (Years) 25–34 285 60% 22 52% 263 61% 0.47 0.74
35–44 151 32% 18 43% 133 31%
45–54 37 8% 2 5% 35 8%
55+ 31 % 00 %31 %
Number of Pregnancies 0–2 199 42% 8 19% 191 44% 0.0002 0.0001
3–4 179 38% 20 48% 159 37%
5–6 62 13% 5 12% 57 13%
$7 31 7% 9 21% 22 5%
Number of Sexual Partners,
Lifetime
{
1–2 145 30% 10 24% 135 31% 0.065 0.026
3–4 145 30% 8 19% 137 32%
5–6 74 16% 10 24% 64 15%
$7 105 22% 14 33% 91 21%
Marital Status Married 58 12% 7 17% 51 12% 0.42 n/a
Unmarried, with partner 110 23% 12 29% 98 23%
Widowed 185 39% 16 38% 169 39%
Separated/Divorced 119 25% 7 17% 112 26%
Oral Contraceptive Use Never Used 408 88% 32 76% 376 87% 0.075 n/a
Ever Used 57 12% 9 21% 48 11%
Number of Gynecologic
Infections*
0 123 26% 9 21% 114 26% 0.73 0.81
1–2 322 68% 31 74% 291 67%
$3 23 5% 1 2% 22 5%
Number of People in Residence 1–2 149 31% 7 17% 142 33% 0.083 0.013
3–4 92 19% 8 19% 84 19%
5–6 143 30% 14 33% 129 30%
$7 84 18% 12 29% 72 17%
CD4 Category (per mm
3) $350 104 22% 7 17% 97 22% 0.76 0.61
200–349 178 37% 17 40% 161 37%
,200 192 40% 17 40% 175 40%
Income (Rwandan Francs) ,10K 166 35% 9 21% 157 36% 0.055 0.017
.10K-#35K 233 49% 22 52% 211 49%
.35K 66 14% 10 24% 56 13%
Current Health Insurance Yes 209 45% 23 55% 186 43% 0.19 n/a
No 260 55% 19 45% 241 56%
Number of Meals with Meat
(weekly)
0 240 50% 15 36% 225 52% 0.1 0.14
1–2 152 32% 19 45% 133 31%
$3 74 16% 7 17% 67 15%
Malarial Infection Never 86 18% 3 7% 83 19% 0.096 0.047
Past 205 43% 19 45% 186 43%
Recent 176 37% 20 48% 156 36%
HPV DNA Status Non-Carcinogenic 160 34% 4 10% 156 36% ,0.0001 ,0.0001
Carcinogenic HPV (excluding
HPV16)
251 53% 24 57% 227 52%
HPV16 65 14% 14 33% 51 12%
Multiple HPV types 243 51% 27 64% 216 50% 0.077 n/a
*self-reported;
{includes incidences of rape; n/a=not applicable.
doi:10.1371/journal.pone.0013525.t001
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genic HPV (ptrend ,0.001). CD4 counts were not related to
cervical histologic findings among all HIV+/HPV+ women.
The results of the three logistic regression models are shown in
Table 2. Of the 476 HPV+ women, 65 (14%) had HPV16, 251
(53%) had carcinogenic HPV other than HVP16, and 160 (34%)
had only non-carcinogenic HPV. Among all HIV+/HPV+
women, factors significantly associated with a histologic diagnosis
of CIN3+ included 7 or more (vs. 0-2) pregnancies (OR =8.7; CI
2.3-32.4), malarial infection in the previous six months (vs. never)
(OR 3.9; CI 1.0-15.2), and 7 or more lifetime sexual partners (vs.
1–2 partners) (OR 2.8; CI 1.1-7.2). Compared to having non
HPV16 carcinogenic genotypes, having HPV16 infection was
positively associated (OR 2.6; CI 1.1-6.1) and having a non-
carcinogenic HPV infection was inversely associated (OR 0.26; CI
0.09-0.81) with CIN3+ (vs. a less severe diagnosis).
Analyses restricted to (all) carcinogenic HPV genotypes showed
significant associations of CIN3+ with $7 pregnancies (vs. 0-2) and
HPV16 (vs. non HPV16 carcinogenic genotypes). In analyses
restricted to women with non-HPV16 carcinogenic HPV, $7
pregnancies (vs. 0-2) were associated with CIN3+. In both restricted
analyses the magnitude of the associations of CIN3+ with 7 or more
lifetime sexual partners and recent malarial infection were similar to
that found in all HPV+ women, but were not statistically significant,
perhaps because of the smaller sample sizes.
Both the magnitude (OR) and strength (p value) of the
association of CD4 count with CIN3+ was greatest in the women
with non-HPV16 carcinogenic HPV (Table 2): per 100 CD4 cells/
ml increase, OR 0.62, CI 0.40-0.97, p=0.035; OR 0.81, CI 0.60-
1.11, p=0.19; and OR 0.84, CI 0.63-1.12, p=0.22 in women
positive for non-HPV16 carcinogenic HPV, any carcinogenic
HPV, and all HPV genotypes, respectively.
Table 2. Multivariate associations of clinical and demographic characteristics with cervical intraepithelial neoplasia grade 3 or
cancer versus less severe than CIN3 among 454 human immunodeficiency virus-infected, human papillomavirus (HPV)-infected
women with complete data.
Any HPV N=454 Carcinogenic HPV n=303
Non-HPV16 carcinogenic HPV
n=241
OR 95%CI OR 95%CI OR 95%CI
Number of Pregnancies
0–2 (ref) 1.00 1.00 1.00
3–4 2.58 1.00–6.64 2.27 0.85–6.05 4.27 1.20–15.22
5–6 1.53 0.39–6.03 1.09 0.23–5.05 0.78 0.07–8.25
$7 8.65 2.31–32.43 6.82 1.67–27.97 7.55 1.26–45.18
Number of Sexual Partners
1–2 1.00 1.00 1.00
3–4 0.59 0.20–1.74 0.50 0.16–1.57 0.59 0.16–2.14
5–6 1.87 0.65–5.37 1.31 0.41–4.13 1.14 0.25–5.19
$7 2.76 1.06–7.20 2.50 0.91–6.89 1.43 0.42–4.87
CD4 Count
per 100 cells/mm
3 0.84 0.63–1.12 0.81 0.60–1.11 0.62 0.40–0.97
Number of People in Residence
1–2 (ref) 1.00 1.00 1.00
3–4 1.67 0.52–5.27 1.67 0.49–5.67 1.50 0.31–7.25
5–6 1.39 0.47–4.17 1.22 0.38–3.95 1.61 0.37–7.01
$7 1.59 0.46–5.48 2.04 0.56–7.39 2.73 0.56–13.38
Income (Rwandan Franc)
#10K (ref) 1.00 1.00 1.00
.10K-#35K 1.55 0.63–3.78 1.37 0.53–3.53 1.07 0.34–3.41
.35K 2.16 0.70–6.65 1.36 0.40–4.60 1.52 0.33–7.06
Malarial Infection
Never (ref) 1.00 1.00
Past 2.95 0.75–11.63 2.42 0.60–9.82 2.94 0.56–15.61
Recent 3.86 0.98–15.24 3.26 0.80–13.34 2.35 0.44–12.48
HPV DNA Status
Non-Carcinogenic 0.26 0.09–0.81
Carcinogenic HPV (excluding HPV16) 1.00 1.00
HPV16 2.62 1.12–6.12 2.93 1.24–6.89
OR=odds ratio; CI=95% confidence interval; n/a=not applicable.
doi:10.1371/journal.pone.0013525.t002
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was independently and positively associated with number of
pregnancies (OR 5.88, CI 1.95-17.77 for $7 compared to 0-2),
number of sexual partners (OR 2.60, CI 1.18-5.73), and inversely
associated with non-carcinogenic HPV (OR 0.25, CI 0.10-0.58).
Unlike in women with CIN3+, CIN2+ was not significantly
associated with harboring HPV16 (OR 1.45, CI 0.68-3.08) or with
recent malarial infection (OR 1.46, CI 0.59-3.59) (data shown in
Supplemental online tables S1 and S2).
Discussion
In this cross-sectional analysis of cervical histology in HIV+/
HPV+ Rwandan women we found that immunosuppression as
measured by CD4 count was significantly associated with CIN3+
only in women who harbored carcinogenic HPV genotypes other
than HPV16. We and others have reported that HPV16
prevalence and incidence are not associated with CD4 count
[12,13], suggesting that HPV16 may be more able than other
HPV genotypes to avoid immune surveillance in immune
competent women. Immunosuppression may differentially affect
the risk of progression to CIN3 and cancer of non-HPV16
carcinogenic HPV genotypes versus HPV16, perhaps mediated
directly through the likelihood of HPV viral persistence. However,
we had inadequate numbers (65) of women testing positive for
HPV16 to allow direct analysis of the association of CD4 count
with CIN3+ in HIV+ women with HPV16 genotype.
Compared to testing positive for non-HPV16 carcinogenic
HPV, CIN3+ was inversely associated with testing positive for
only non-carcinogenic HPV and positively associated with
testing positive for HPV16. Notably, the fraction of women
with CIN3+ who tested positive for HPV16 was less than
expected (33% in this study versus 50–60% in other studies) and
the strength of association and magnitude of the odds ratio for
the association of HPV16 with CIN3+ were smaller than
a n t i c i p a t e d .T h i si sf u r t h e ra l b e i ti n d i r e c te v i d e n c et h a tt h e
relative effects of HPV16 in the development of cervical cancer
may be less enhanced in HIV-infected compared to uninfected
women, consistent with our prior report [12]. The other AIDS-
defining cancers, Kaposi’s Sarcoma and large B-cell lymphoma,
have demonstrated dramatically decreased incidence since the
advent of effective antiretroviral therapy (ART) [21,22], which
reverses much of the immune compromise of HIV infection.
However, the HPV-related cancers, invasive cervical cancer and
anal carcinoma, have in most reports not decreased in incidence
in the era of effective ART [21–23]. This may be in part due to
the lack of impact of immune suppression with HPV16 natural
history, which inmost populations causesat least 50% of cervical
cancers.
We found that recent malarial infections had a significant
positive association with CIN3+ in HIV+/HPV+ women. To our
knowledge, this is the first report of any evidence that malarial
infections might contribute to the risk of cervical precancer and
cancer. The mechanisms by which malarial infections could
increase the risk of CIN3+ are unknown, but might include
additional challenges to the already compromised immune
system of HIV+ women. HIV, HPV and malarial infections are
highly prevalent in much of Africa, and any increased risk of
CIN3+ associated with malaria could result in a substantial
attributable risk. However, given the limited sample size in this
analysis, this observation needs to be confirmed in other
populations.
Several factors previously identified as associated with cervical
precancer and cancer in general populations of women were also
identified here in HIV+/HPV+ Rwandan women. We found
that multiple pregnancies (7 or more) were associated with
increased risk of CIN3+, independent of number of reported
sexual partners. High parity has been reported as a risk factor for
cancer in populations of unknown HIV serostatus [9]; the
mechanism by which parity increases the risk is unknown but
may be related to endogenous hormones causing further eversion
of the squamocolumnar junction and/or tissue damage and
inflammation resulting from birthing. A higher number of sexual
partners was also associated with CIN3+, perhaps reflecting
greater likelihood of multiple HPV exposures and thus stochas-
tically to greater opportunity for HPV persistence and progres-
sion to CIN3+.
Our study has several limitations. It is a cross-sectional analysis
and temporal or causal relationships cannot be inferred. The lack
of follow-up does not allow observation of progression with
specific HPV types. An additional limitation of this study is that
HPV+ women without clinical indication of abnormal cytology
or visual lesions were not colposcoped and therefore not biopsied.
Thus visually unapparent, HPV+ high-grade lesions could have
been missed [24], resulting in verification bias. We expect that
this may have muted the strength of association by misclassifying
some cases of CIN3+ as controls. Potential misclassification of
women as HPV+ may have resulted from the use of CVL rather
than tissue to determine HPV infection, thus eliminating from
the population women who were in fact HPV infected. It may
also have led to over-representation of non-carcinogenic HPV
genotypes that preferentially infect the vagina [25,26]. Further,
cross-sectional detection of HPV is only a proxy for lifetime level
of exposure. The smaller magnitude of the association of CIN3+
with CD4 count may not have been sufficient to achieve
statistical significance because of the small number of women
with HPV16. We also could not distinguish prevalent from
incident infection. This may lead to underestimating the
association of HR-HPV with CIN3 and cancer since prevalent
infections represent a mixture of incident and persisting
infections, the latter of which are on the causal pathway to
cervical precancer and cancer.
In conclusion, we found that CIN3+ was inversely associated
with CD4 cell count in HIV+ women co-infected with non-
HPV16 carcinogenic HPV. The implication of these data is that a
greater proportion of cervical precancer and cancer may be
attributable to carcinogenic HPV genotypes other than HPV16 in
HIV+ women compared to HIV-negative women but larger
studies are needed to evaluate this directly. We also found some
evidence that malarial infections may increase the risk of CIN3+;
this warrants confirmation in larger population-based studies.
Supporting Information
Table S1 Demographic and clinical characteristics in human
immunodeficiency virus-infected, human papillomavirus (HPV)-
infected women with and without cervical intraepithelial neoplasia
grade 2 or more severe (CIN2+)
Found at: doi:10.1371/journal.pone.0013525.s001 (0.11 MB
DOC)
Table S2 Multivariate associations of clinical and demographic
characteristics with cervical intraepithelial neoplasia grade 2 or
more severe versus less severe than CIN2 among 454 human
immunodeficiency virus-infected, human papillomavirus (HPV)-
infected women with complete data.
Found at: doi:10.1371/journal.pone.0013525.s002 (0.07 MB
DOC)
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